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Edited by Robert B. RussellAbstract We performed a docking study followed by a 500-ps
molecular dynamics simulation of R-state human adult hemoglo-
bin (HbA) complexed to diﬀerent heterotropic eﬀectors [2,3-
diphosphoglycerate (DPG), inositol hexaphosphate (IHP), and
2-[4-[(3,5-dichlorophenylcarbamoyl)-]methyl]-phenoxy]-2-meth-
ylpropionic acid (RSR13)) to propose a molecular basis for re-
cently reported interactions of eﬀectors with oxygenated
hemoglobin. The simulations were carried out with counterions
and explicit solvation. As reported for T-state HbA, the eﬀector
binding sites are also located in the central cavity of the R-state
and diﬀer depending on eﬀector anionic character. DPG and
IHP bind between the a-subunits and the RSR13 site spans the
a1-, a2- and b2-subunits. The generated models provide the ﬁrst
report of the molecular details of R-state HbA bound to hetero-
tropic eﬀectors.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Human adult hemoglobin (HbA) is a tetrameric protein con-
sisting of two ab dimers that cooperatively binds and releases
oxygen. In performing its function, HbA undergoes major ter-
tiary and quaternary conformational changes as it equilibrates
between a low-aﬃnity deoxy T-state and a high-aﬃnity oxy R-
state [1].
The ab dimers are arranged around a twofold symmetry
axis, which yields a central cavity that is larger in the T-state.
During the transition to the R-state, signiﬁcant subunit reposi-Abbreviations: HbA, human adult hemoglobin; DPG, 2,3-diphospho-
glycerate; IHP, inositol hexaphosphate; RSR4, 2-[4-[(3,5-dichlorophe-
nylcarbamoyl)-]methyl]-phenoxy]-2-methylpropionic acid; RSR13,
2-[4-[(3,5-dimethylphenylcarbamoyl)-methyl]-phenoxy]-2-methylprop-
ionic acid; TB5-27, 1,3-phenylene[bis(2-[4-[(aminocarbonyl)-methyl]-
phenoxy]-2-methylpropionic acid; MD, molecular dynamics; MWC,
Monod–Wyman–Changeux model
*Corresponding author. Fax: +36 1 266 6656/215 898 7064.
E-mail addresses: laberge@puskin.sote.hu,
labergem@mail.med.upenn.edu (M. Laberge).
0014-5793/$30.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.12.033tioning occurs upon oxygen binding. The salt bridges that con-
strain the T-state are broken by the rotation of one of the ab
dimers relative to the other, and the a1b2 and a2b1 interface
contacts are reorganized, yielding a structure in which the b1
heme to b2 heme distance is 6.5 A˚ longer and with narrower
central cavity [2,3].
X-ray crystallographic studies have revealed speciﬁc binding
sites in the T-state central cavity for several types of hetero-
tropic eﬀectors (=not heme bound) that lower the oxygen aﬃn-
ity of HbA. The ﬁrst site identiﬁed was that of the natural
eﬀector present in red blood cells, 2,3-diphosphoglycerate
(DPG), found to bind HbA in a 1:1 stoichiometry [4,5]. It is
located at the entrance of the cavity between the two b-sub-
units that contribute positively charged residues to comple-
ment the negatively charged DPG phosphate groups, namely
val1, his2 and lys82 of both b chains (Fig. 1). Other negatively
charged eﬀectors, such as inositol hexaphosphate (IHP) – the
analog of the avian natural eﬀector inositol pentaphosphate,
inorganic phosphate and polyglutamic acid, also bind this site,
commonly referred to in the literature as the ‘‘DPG site’’ [6].
The central cavity contains binding sites for other classes of
eﬀectors – most notably the series of antilipidemic eﬀectors de-
rived from cloﬁbrate [7] and bezaﬁbrate (BZF) [8,9], that are
all potent eﬀectors in reducing the oxygen aﬃnity of T-state
HbA. Unlike DPG and IHP, these eﬀectors bind at least two
molecules in the middle of the cavity. Among recently pub-
lished structures, that of the HbA–RSR13 complex shows
two RSR13 molecules bound in the cavity to the residues of
two a-chains and one b-chain in twofold symmetry-related
sites, referred to as primary occupancy sites or as the BZF sites
[10]. Secondary sites are also reported for this class of eﬀectors
as described for the HbA–2-[4-[(3,5-dichlorophenylcarba-
moyl)-]methyl]-phenoxy]-2-methylpropionic acid (RSR4) com-
plex in which four RSR4 molecules simultaneously bind the
central cavity, two at the same sites as BZF and RSR13 (pri-
mary sites) and two additional molecules at symmetrically
equivalent secondary sites [11]. The X-ray structure of
T-HbA complexed to another BZF-analog, namely 1,3-
phenylene[bis(2-[4-[(aminocarbonyl)-methyl]phenoxy]-2-meth-
ylpropionic acid (TB5-27), shows how two TB5-27 molecules
bind the central cavity, their length (double that of RSR4)
allowing to simultaneously bridge both primary and secondary
sites [12] (Fig. 2).
Recently, a new model was proposed to fully account for
HbA function [13], while providing a new interpretation of
eﬀector interactions and a reformulation of the Monod–blished by Elsevier B.V. All rights reserved.
Fig. 1. The central cavity of T-state HbA showing the DPG binding
site between the b-subunits. Image constructed using the RCSB X-ray
coordinates 1B86. DPG is rendered as ball and stick, the stabilizing
positive residues are yellow, namely b1-val1, -his2 (top), b1-lys85 (left),
b2-val1, -his2 (bottom), and b2-lys85 (right). Both b-chains are colored
by atom, the a1 subunit is purple and a2 is blue.
628 M. Laberge et al. / FEBS Letters 579 (2005) 627–632Wyman–Changeux (MWC) and related models for allosteric
behavior. In this new model, heterotropic eﬀectors are consid-
ered as primarily responsible for the regulation of oxygen aﬃn-
ity in that eﬀector-linked tertiary changes – rather than the
quaternary transition linked to oxygen binding, regulate coop-
erativity. The eﬀect of heterotropic eﬀectors on HbA function
had long been taken into account in previous models, – most
notably by Perutzs stereochemical model [14,15], but with a
rationale that had eﬀectors bind only T-state HbA. In thisFig. 2. T-state HbA bound to potent BZF analogs. Left: Two molecules of R
Right: Two long molecules of TB5-27 (yellow) line both primary and secon
1K0Y). Subunits are colored as follows: a1 pink, b1 turquoise, a2 blue, andview, eﬀectors lower the oxygen aﬃnity by stabilizing the T-
state salt bridges between the b-subunits as they bind the larger
T-state central cavity. Yet, a considerable body of experimen-
tal evidence had long shown that heterotropic eﬀectors did
interact not only with T, but also with R-state HbA [16–20].
DPG was reported to speciﬁcally bind both R- and T-state
HbA, albeit the T-state 50% more strongly [16] while IHP
was observed to bind the R-state even more strongly than
the T-state [18]. More recently, compelling evidence was pro-
vided by Yonetani et al. [13,21–23]. Careful analyses of HbA
oxygenation curves led the authors to conclude that – contrary
to accepted belief – heterotropic eﬀectors control oxygenation
by binding not only T, but also R-state HbA (cf. ﬁgure 9 in
Ref. [13]).
These results prompted us to initiate docking studies so as
to gain insight into the molecular basis of heterotropic eﬀec-
tor binding to R-state HbA. The diﬃculty of growing good
quality crystals of R-state human hemoglobin bound to
eﬀectors is well-known [24,25]. To date, the only X-ray
structure reported for a R-state Hb bound to an eﬀector is
that of horse hemoglobin complexed to BZF [26]. However,
the sequence homology of horse and human Hb diﬀers by
18%, hence the appropriateness of a computational ap-
proach to investigate the molecular basis of eﬀector binding
to HbA.2. Materials and methods
2.1. Docking
R-state tetrameric HbA was docked to DPG, IHP, and RSR13.
Initial coordinates were obtained from the RCSB repository, namely
1HHO (R-state HbA) [27], 2HHB (T-state HbA) [28], 1THB (T-state-
IHP complex) [29], 1B86 (T-state-DPG complex) [30], and 1G9V (T-
state-RSR13 complex) [31]. The 1HHO structure contains only one
dimer and the second was constructed by symmetry to obtain tetra-
meric R-HbA. The stereochemical quality of all structures was veri-
ﬁed and corrected using the PROCHECK program [32] and all
structural waters with low B-factors were retained. Global range
molecular matching (GRAMM) [33], based on the molecular recogni-SR13 (yellow) bind the central cavity in symmetry-related primary sites.
dary sites in the central cavity. (RCSB X-ray coordinates 1G9V and
b2 green.
Table 1
Average RMS deviations A˚ of the MDS-generated structures from the
structures obtained after docking HbA to eﬀectors
DPG IHP RSR13
Backbone 2.54 3.00 2.60
Whole protein 3.02 3.41 3.10
Sidechains 3.24 3.62 3.36
Eﬀector 2.99 3.48 4.26
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dock the eﬀectors to R-state HbA. The program outputs a list of
eﬀector positions with corresponding scores, which are proportional
to the intermolecular energy calculated with a simpliﬁed potential
function [33]. We used the high-resolution generic docking algorithm
with a grid step of 1.7 A˚ and a grid size of 64 A˚. The eﬀector was
rotated with 10 angle intervals for each complex. The energy score
for repulsion was 10 and 0.5 for attraction. A total of 1000 docking
scores were computed with the 10 best scores retained for energy
minimization. After minimization, the lowest-energy complexes were
selected as best ﬁt and submitted to molecular dynamics (MD) sim-
ulations for optimization of the HbA tertiary structure with docked
eﬀector. The docking results were controlled by also docking DPG
to T-state HbA, which yielded best scores in all features similar to
the published X-ray coordinates [30]: DPG also docked at the en-
trance of the cavity between the two b subunits as is the case in
the X-ray structure site and the DPG solvent accessible surface area
calculated for the best docked scores averaged 160.86 A˚2 (cf.
162.73 A˚2 for the X-ray structure).
2.2. Energy minimization and molecular dynamics
The forceﬁeld and solvation. All simulations were performed using
CHARMM version c29b2 with the all-atom-27 protein forceﬁeld in-
cluded in the distribution [35] and with NAMD2 [36]. The eﬀectors
were parametrized as follows: initial structures were extracted from
the available X-ray structures of the T-state bound complexes. Ab
initio density functional theory geometry optimizations at the
B3LYP level were performed using GAMESS [37]. Mulliken charges
were obtained from HF/6-31G\ calculations and were incorporated
into the forceﬁeld. Other parameters were derived following the
CHARMM parametrization protocol [38]. Explicit hydrogens were
added using HBUILD consistent with pH 7.0. The HbA-eﬀector
complexes were gently minimized in vacuo using a conjugate gradient
algorithm to eliminate unfavorable crystal interactions. Harmonic
constraints were applied to heavy atoms to achieve smooth minimiza-
tion. The harmonic force constant was decreased every 100 steps,
from 200, 100, 75, 25, 10, and 5 kcal/mol/A˚2, followed by uncon-
strained minimization for 300 steps. To achieve charge neutrality,
counterions were added using Helmut Grubmuellers Solvate 1.0
algorithm [39] which places Na+ and Cl counterions at physiological
concentration (0.154 mol/l) according to a Debye–Hu¨ckel distribu-
tion, followed by a large number (2000000) of Monte-Carlo equili-
bration steps. The complexes and counterions were placed with
equilibrated TIP3 waters at 300 K in a truncated octahedron cell
(86 · 78 · 60 A˚), which represented a total of some 53300 atoms.
All TIP3 molecules that overlapped either protein, counterions or
structural water molecules with a distance between heavy atoms less
than 2.8 A˚ were deleted. Solvent and counterions were minimized
with the respective complexes held at ﬁxed positions using 100 steps
of steepest descent. A second minimization was performed on the
whole system with progressively decreasing harmonic constraints as
described above. Simulations were performed with the dielectric con-
stant set equal to 1. All hydrogen bonds were constrained during the
simulations using the SHAKE algorithm [40] with an integration
time-step of 1 fs. The system was simulated as an ensemble with con-
stant number of atoms, constant pressure and temperature (NPT)
with periodic boundary conditions using CHARMMs crystal facility.
Coordinates were saved every 10 ps and the non-bonded lists were
updated heuristically. Full electrostatics were calculated using the
particle mesh Ewald (PME) method [41] with a grid spacing on the
order of 1 A˚ or less. The PME implementation in CHARMM splits
the electrostatic interaction energy into two parts. For the short-
range direct summation part, the list of non-bonded interactions
was truncated at 13 A˚. For the long-range reciprocal Ewald sum, a
real space Gaussian width j = 0.34 A˚1 was used [42] with order 6.
The van der Waals interactions were treated with an atom-based
non-bond cutoﬀ of 12 A˚ and a switching function between 10.0
and 12.0 A˚. The Hoover method was used to maintain constant tem-
perature [43] and constant pressure was maintained using the Lange-
vin piston method [44] with a piston mass of 400 amu, a piston
temperature of 300 K with a damping coeﬃcient c of 10 ps1. Lange-
vin dynamics was used throughout 500-ps simulation runs, following
a heating stage that brought the system to the desired temperature in
25 increments of 10 K followed by 100 ps-equilibration dynamics be-
fore the 500 ps-production dynamics.3. Results and discussion
Molecular recognition incorporates both geometrical and
molecular interaction aspects [45]. The computational algo-
rithm used for our docking study includes a geometry-based
docking algorithm that searches for the best steric or hydro-
phobic ﬁt for the protein–eﬀector complex, performing an
exhaustive six-dimensional search for all possible conforma-
tions. Surprisingly, all best scores were indicative of a speciﬁc
binding site within the central cavity for all HbA–eﬀector com-
plexes when the docking was performed at high resolution.
The lack of unspeciﬁc binding is indicative of a high level of
recognition between R-state HbA and the eﬀectors.
During the dynamics, the HbA-eﬀector structures undergo
rearrangements as shown by the average root-mean-square
deviations (rmsd) of the trajectory average structures from
the starting structures obtained from docking (cf. Table 1).
As expected, the binding of the bulkier and more highly
charged IHP requires more protein reorganization with an
average backbone rmsd of 3.00 A˚ when compared to that of
DPG and RSR13 (2.54 and 2.60 A˚, respectively). As for the
eﬀectors, they all show rmsd values close to or above 3 A˚ with
the highest value obtained for the more ﬂexible RSR13
(4.26 A˚). Taken together, these values show that the protein
matrix rearranges signiﬁcantly as it accommodates the various
eﬀectors.
Fig. 3 shows the average structure obtained after 500 ps MD
for the HbA–DPG and the HbA–RSR13 complexes and Figs.
4 and 5 provide a detailed view of the binding sites.
DPG and IHP bind R-HbA at the same site, located in the
central cavity between the a1- and a2-subunits. They are stabi-
lized by an extensive H-bond network to a2-arg141, a1-arg141,
a2-lys99, a1-lys99 and to cavity water molecules that also act as
H-bond bridges between eﬀector and residues (Fig. 4 and Ta-
ble 2). This site is analogous to the T-state site located between
the b-subunits. The RSR13 site is diﬀerent. Only the methyl-
propionic acid group at one end of the eﬀector molecule is held
by a few H-bonds to a2-arg141 and a1-lys99 and to a cavity
water (Fig. 5, Table 2). The aromatic end of the RSR13 mol-
ecule is stabilized by an aromatic-aromatic interaction between
an eﬀector ring and the b2-tyr35 ring. Normal to each other,
the rings present an optimal geometry for this type of interac-
tion [46]. Additionally, the following residues provide hydro-
phobic stabilization: a2-leu29 (5.11 A˚), a2-leu34 (2.64 A˚), and
b2-val34 (5.96 A˚). With RSR13 bound to two a-subunits and
one b, the R-site is analogous to the secondary site occupied
by the second RSR13 in T-state HbA [31].
During the time-scale of the simulation (500 ps), the eﬀectors
do not exhibit high mobility, DPG and IHP remaining in the
vicinity of the a1- and a2-subunits and RSR13 close to the
a1-, a2- and b2-subunits as shown by the small amplitude of
their respective rms deviations during the production dynamics
(Fig. 6). We note also that, unlike DPG and IHP, RSR13
Fig. 4. Stereoview of the R-state DPG (top) and IHP (bottom) binding
sites. Average docked structure obtained after 500 ps-MDS. DPG is
held by a H-bond network to a2-arg141, a1-arg141, a2-lys99, a1-lys99
(clockwise from top left) and to cavity waters. IHP is held by a similar
H-bond network with the same residues (also shown clockwise from
top left) and cavity waters.
Fig. 5. Stereoview of the R-state RSR13 binding site. Average docked
structure obtained after 500 ps-MDS. The polar end of RSR13 is held
by H-bonds to a2-arg141 and a1-lys99 and to a cavity water. Note
aromatic–aromatic interaction between a ring of RSR13 and b2-tyr35
at the other end of the eﬀector molecule.
Fig. 3. R-state HbA bound to DPG (left) and RSR13 (right). Average docked structure obtained after 500 ps-MDS. Subunits are colored as in
Fig. 2.
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tion MDS stages (cf. starting values in Fig. 6), a reﬂection of its
more ﬂexible structure and lack of strong anionic character,
which is also reﬂected in its slightly higher rms values.
Fig. 7 shows the RMS deviations between the 500-ps trajec-
tory average and the starting structure for all three HbA com-
plexes. Bearing in mind that both a-subunits each number 141
residues and both b-subunits 146, we note that not only the
four chain termini residues exhibit enhanced ﬂexibility, but
also helical regions, namely the a136 to a151, b141 to b153,
b181 to b187, a237 to a275, and b247 to b292 regions for the
DPG complex (dark blue trace) and the b139 to b149, b179
to b184, and a250 to a264 regions for IHP complex (purple
trace), all of which are indicative of tertiary structure reorgani-zation and ﬂexibility. As for the RSR13 complex, maximum
ﬂuctuations also occur in the b139 to b187 and b250 to b280 re-
gions. Comparison with the HbA trace without eﬀectors (pale
blue) shows that the ﬂuctuations are signiﬁcantly damped in
the absence of eﬀectors – a result that may support the asser-
tion of Yonetani et al. [13] to the eﬀect that tertiary rather than
quaternary changes mediated by heterotropic eﬀectors are
responsible for regulating oxygen aﬃnity.
The two classes of eﬀectors modeled in this study, i.e., the
anionic type (DPG, IHP) and the BZF-analog type (RSR13),
do not bind the same type of site and it is noteworthy that this
is also the case for the sites identiﬁed in the T-state-eﬀector
complexes for which X-ray structures are available [29–31].
Our modeling results are consistent with binding site speciﬁcity
for both T- and R-state HbA in the central cavity: both T-state
and R-state central cavities bind one anionic-type eﬀector
(DPG, IHP) and as for the cloﬁbrate and BZF-analogs, T-state
binds at least two eﬀectors in the central cavity at primary and
secondary sites, while R-state binds one in its central cavity.
Of particular interest is the DPG binding site modeled for R-
state HbA, since DPG is the natural allosteric eﬀector found in
human red blood cells. A study reporting on the 1:1 stoichiom-
Table 2
H-bonding network of the eﬀector binding sites averaged over the 500-
ps trajectories
Atom contacts dave (A˚)
DPG site
DPG-O13 – a1arg141-NH1 2.57
DPG-O5 – a1arg141-NH2 2.87
DPG-O2 – a1lys99-NZ 2.89
wat639-O – a2arg141-NH2 2.64
DPG-O9 – wat639-H1 1.62
DPG-O10 – a2lys99-NZ 2.86
DPG-O11 – a2lys99-NZ 2.66
DPG-O7 – wat672-H1 1.78
DPG-O11 – wat638-H1 1.81
DPG-O11 – wat747-H2 2.75
DPG-O11 – wat591-H1 1.84
DPG-O13 – wat591-H2 1.70
IHP site
IHP-O22 – a1lys99-NZ 2.84
IHP-O46 – a1lys99-NZ 2.69
IHP-O12 – a1lys99-NZ 2.94
IHP-O41 – a1lys99-NZ 2.75
IHP-O24 – a2lys99-NZ 2.89
IHP-O47 – a1arg141-NH1 3.18
IHP-O45 – a1arg141-NH1 2.64
IHP-O18 – a1arg141-NH1 2.74
IHP-O26 – a1arg141-NH2 2.79
IHP-O36 – a2arg141-NH1 2.58
IHP-O31 – a2arg141-NE 2.66
IHP-O42 – wat638-H1 1.73
IHP-O42 – wat639-H1 1.76
IHP-O44 – wat591-H2 1.67
IHP-O26 – wat599-H1 1.84
IHP-O26 – wat747-H1 1.70
RSR13 site
RSR13-O2 – a2arg141-NH2 2.78
RSR13-O3 – a1lys99-NZ 2.77
RSR13-O2 – w747-H1 2.10
RSR13-O2 – w707-H2 2.37
RSR13-O2 – w707-H1 1.76
w747-O – a2arg141-NH1 2.74
Fig. 7. Distribution of residue rms deviations between the 500-ps
trajectory average and the starting structure (after heating and
equilibration). Traces: R-state HbA–DPG (blue), R-state HbA–IHP
(purple), R-state HbA–RSR13 (yellow). R-state without eﬀectors (pale
blue).
Fig. 6. Eﬀector atom rms deviations from the starting equilibrated
structure during the course of the simulations. Traces: DPG (purple),
IHP (blue), RSR13 (red).
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lated that only one molecule of DPG should bind the central
cavity in both states, while interacting with diﬀerent cavity res-
idues in deoxy- and oxy-HbA [16]. Our results are in goodagreement with these results, as DPG binds the central cavity,
but in a site diﬀerent from that of T-state HbA.
Due to the high computational cost of our study, we did not
attempt to dock a second eﬀector to our R-models, thus it is
entirely possible that a second site may be present, but not
in the central cavity. Inspection of the cavity clearly shows that
steric constraints would be too high to accommodate a second
eﬀector, in good agreement with reported 1:1 binding stoichi-
ometries for R-state HbA [16,18,19].4. Conclusions
In this work, we used a combined docking and MD ap-
proach to generate models of R-state HbA bound to DPG,
IHP and RSR13. The most unexpected result of this study is
that – as reported for T-state HbA, the R-state also shows spe-
ciﬁc binding sites in the HbA central cavity for heterotropic
eﬀectors, sites that also diﬀer depending on the anionic charac-
ter of the eﬀectors as previously reported for T-state HbA. The
generated models provide the ﬁrst description of the molecular
details of R-state HbA bound to two diﬀerent classes of het-
erotropic eﬀectors and the ﬁrst indication that eﬀector binding
aﬀects tertiary structure ﬂuctuations. Details of the compara-
tive dynamics of R- and T-state HbA–eﬀector complexes will
be reported elsewhere. The models were deposited at the RCSB
repository but the accession code is not yet known.
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